Ramucirumab, an anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody, has demonstrated efficacy in unresectable HCC with serum alpha-fetoprotein (AFP) levels of ≥400 ng/mL that is refractory or intolerant to sorafenib.3 The gene discussed is AFP; the disease is hepatocellular carcinoma.